Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07808827) titled 'A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma' on Sept. 2.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shanghai Junshi Bioscience Co., Ltd.
Condition:
Diffuse Large B-Cell Lymphoma
Intervention:
Combination Product: JS203 in combination with gemcitabine and oxaliplatin
Recruitment Status: Not recruiting
Phase: Phase 3
Date of Fir...